ABOUT COLLAGILE

Collagile GmbH is a leading German provider of nutritional and feed supplements based on bioactive collagen peptides. The company stands for innovative and highly effective products that promote the health and mobility of both humans and animals. These high-quality solutions are available in pharmacies, specialty stores, and the company’s online shop.
 

TRANSACTION BACKGROUND

The shareholders of Collagile GmbH have consciously chosen to sell their shares to the financially strong and entrepreneurially driven investor Rivus Capital, ensuring a forward-looking development of the company. 

Rivus Capital’s extensive industry expertise, broad network, and hands-on operational approach create optimal conditions for scaling and internationalizing the Collagile business.
 

SOLUTION

The shareholders found an experienced and reliable partner in Dr. Bartels M&A Consulting (BMA), who successfully guided them through this process.
With this strategic decision, a sustainable succession plan at both the shareholder and management levels was initiated early on. Following the transaction, Manfred Hinrainer, founder of Collagile, will work closely with Rivus Capital to strengthen the management team and ensure a structured transition of leadership.

The BMA team exclusively advised the sellers throughout the entire acquisition process – from identifying and approaching potential investors to supporting the due diligence process and negotiating the final contracts.